FDA Approves Invokana (canagliflozin) to Reduce the Risk of Heart Attack, Stroke or Cardiovascular Death in Adults with Type 2 Diabetes and Established Cardiovascular Disease
TITUSVILLE, NJ, October 30, 2018– The Janssen Pharmaceutical Companies of Johnson& Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved Invokana (canagliflozin) to reduce the risk of major adverse...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
More News: Canagliflozin | Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Drugs & Pharmacology | Endocrinology | Food and Drug Administration (FDA) | Heart | Heart Attack | Invokana | Stroke